1. Welcome and Introduction Moderator: John Bartlett, MD Discussants: Cal Cohen, MD Ian Frank, MD Moderator: John Bartlett, MD Discussants: Cal Cohen, MD Ian Frank, MD

2. Accreditation Statement The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Credit Designation Statement: The Johns Hopkins University School of Medicine designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credits ™. Physicians should only claim credit commensurate with the extent of their participation in the activity. To obtain CME credit, on the home page of this program under the heading “Instructions for Obtaining Continuing Medical Education Credit” there is a “CME Post Test and Evaluation” link that take you to the CME test.

3. This program is made possible through an educational grant from Merck & Co., Inc.

4. Program Objectives At the conclusion of this activity the participant should be able to: 1.Integrate and discuss the clinical use and balancing of drug, regimen and patient characteristics that have been demonstrated in clinical trials to be predictive of ARV treatment success. 2.Analyze current clinical trial data on treatment of ARV-naïve and ARV-experienced patients and use this information to select ARV drugs and regimens that maximize the chance for virologic success, avoidance of toxicity and long-term adverse events and minimize the risk of loss of future treatment options. 3.Incorporate into clinical decisions the differences between various classes of ARVs, and different ARV agents within classes, regarding virologic and immunologic efficacy, safety and likelihood of resistance. 4.Describe and explain the key new clinical trials on ARV therapy and ARV therapy strategies presented at the 16th CROI.

5. Course Directors John Bartlett, MD Professor of Medicine Johns Hopkins School of Medicine Baltimore, Maryland Calvin J. Cohen, MD, MS Research Director, CRI New England Clinical Instructor, Harvard Medical School Boston, Massachusetts

6. Faculty Rafael E. Campo, MD University of Miami School of Medicine Miami, Florida Eric Daar, MD David Geffen School of Medicine at UCLA Los Angeles, California Edwin DeJesus, MD Orlando Immunology Center Orlando, Florida Richard A. Elion, MD George Washington University Medical Center Washington, DC Ian Frank, MD University of Pennsylvania Philadelphia, Pennsylvania Trevor Hawkins, MD Southwest CARE Center Santa Fe, New Mexico Graeme J. Moyle, MD, MB, BS Chelsea & Westminster Hospital London, England Paul Sax, MD Harvard Medical School Boston, Massachusetts Luther A. Virgil, Jr., MD National Minority Clinical Research Association Fairfield, New Jersey

7. Disclosures As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of the Johns Hopkins University School of Medicine to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or a sponsor has with the manufacturers of any commercial products discussed in an educational presentation. The disclosures of the faculty for this program can be found in your handout materials and are presented in the following slides:

8. Course Director Disclosures John Bartlett, MD Consulting Agreements: Johnson & Johnson; Tibotec; Merck & Co. Speakers' Bureau/Honorarium Agreements: Abbott Labs, Merck & Co. Financial Interests/Stock Ownership: None Other Financial or Material Support: DSMB; Tibotec Cal Cohen, MD Sources of Funding for Research: Abbott; Bristol-Myers Squibb; Gilead; GlaxoSmithKline; Roche; Pfizer; Tibotec; Merck; Boehringer Ingelheim; Panacos, Tobira, Myriad. Consulting Agreements: Abbott; Bristol-Myers Squibb; Gilead; GlaxoSmithKline; Merck; Pfizer; Tibotec, Boehringer Ingelheim; Panacos. Speakers' Bureau/Honorarium Agreements: Abbott; Bristol-Myers Squibb; Gilead; GlaxoSmithKline; Merck; Pfizer; Tibotec; Virco Financial Interests/Stock Ownership: None. Other: ViralEd, LLC.

9. Discussant Disclosures Cal Cohen, MD Sources of Funding for Research: Abbott; Bristol-Myers Squibb; Gilead; GlaxoSmithKline; Roche; Pfizer; Tibotec; Merck; Boehringer Ingelheim; Panacos, Tobira, Myriad. Consulting Agreements: Abbott; Bristol-Myers Squibb; Gilead; GlaxoSmithKline; Merck; Pfizer; Tibotec, Boehringer Ingelheim; Panacos. Speakers' Bureau/Honorarium Agreements: Abbott; Bristol-Myers Squibb; Gilead; GlaxoSmithKline; Merck; Pfizer; Tibotec; Virco Financial Interests/Stock Ownership: None. Other: ViralEd, LLC Ian Frank, MD Grant Research: Merck & Co.; Bavarian Nordic; Tibotec Consulting Agreements: BMS; GSK; Pfizer; Gilead Sciences; Tibotec; Abbott Labs Speakers' Bureau/Honorarium Agreements: BMS; GSK; Pfizer; Gilead Sciences; Tibotec; Abbott Labs Financial Interests/Stock Ownership: None Other Financial or Material Support: None This presentation will include information on studies and data presented at the 16 th CROI involving off-label uses of efavirenz, tenofovir, emtricitabine, atazanavir, raltegravir, interleukin-2, GS-9350, SPI-452 and rosiglitazone.

10. The Johns Hopkins University School of Medicine takes responsibility for the content, quality, and scientific integrity of this CME activity.

11. Topics When to Start Preferred NRTIs Switching ARVs in Virologically Suppressed Patients Significance of ARV Pharmacokinetics Studies to Know